ArticleEBioMedicine2025
MyD88 signalling in B cells and antibody responses during Oropouche virus-induced neurological disease in mice.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Emerging threat of Oropouche virus: Clinical features, experimental models, and virulence.Virulence · 2026Review
- Transmission dynamics of Oropouche virus in Latin America and the Caribbean.Nature medicine · 2026Article
- Preclinical Models of Oropouche Virus Infection and Disease.Pathogens (Basel, Switzerland) · 2025Review
- A system to rapidly develop a bunyavirus pseudotyped virus neutralisation assay for pandemic preparedness.NPJ vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
backgroundOropouche virus (OROV) is a neglected insect-borne orthobunyavirus that causes a febrile illness, neurological disease, and pregnancy complications in humans across an endemic area spanning South and Central America. The host factors associated with disease pathogenesis have nonetheless remained obscure, and little is known about the immune determinants of protection against OROV.
methodsWe tracked morbidity, mortality, viral loads, and serum neutralisation in wild-type (WT), Rag1
findingsIn line with a protective role for B cells, WT mice efficiently produced OROV-specific antibodies within 6 days of infection. Serum transfer containing neutralising IgM from WT to Rag1
interpretationEarly MyD88 signalling in B cells is required for optimal antibody responses that limit viral replication and neurological disease in mice infected with OROV.
fundingSão Paulo Research Foundation (FAPESP), National Council for Scientific and Technological Development (CNPq), Coordination for the Improvement of Higher Education Personnel (CAPES), Unicamp Research Affairs Office, PIPAE University of São Paulo, Wellcome Trust, and National Institute of Science and Technology on Photonics Applied to Cell Biology (INFABIC, Unicamp).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.